Fig. 10

Irbesartan significantly suppressed cancer stemness and iron metabolism in PDAC. A-D Q-PCR for c-Jun/SOX9/SOX2/NANOG/OCT4/FTH1/FTL/TFRC were performed in indicated PDX and PDO lines treated with irbesartan (1 μM, 72 h). E Western blot for c-Jun/SOX9/SOX2/NANOG/OCT4/FTH1/FTL/TFRC were performed in indicated PDX and PDO lines treated with irbesartan (1 μM, 72 h). F Percentage of CSCs (CD24⁺CD44⁺ cells, ALDH⁺ cells and CD133⁺ cells) in indicated PDX and PDO lines treated with irbesartan (1 μM, 72 h). G Sphere/organoid number in indicated PDX and PDO lines treated with irbesartan (1 μM, 72 h). H-J Iron metabolism level in indicated PDX and PDO lines treated with irbesartan (1 μM, 72 h) were determined. Statistical analysis of cellular iron content (H), transferrin uptake capacity (I) and LIP (J) was shown. K-L In vivo limited dilution assays for indicated cell lines were performed. Representative tumor incidence and CSC probabilities were shown. M–N Tumor iron content each group in mice of Fig. 7K was measured. Representative images of iron assay each group (M) and statistical analysis (N) were shown. All experiments were repeated three times independently. Paired Student’s t-test were used for in vitro experiments. Un-paired Student’s t-test were used for in vivo experiments